U.S. MarketsIMPORTANT
Eli Lilly and Company (LLY) Q3 2026 (USD): adj. EPS 7.48 (exp. 5.68), Revenue 24.4bln (exp. 22.58bln); Mounjaro 10.7bln (exp. 9.95bln), Zepbound 5.3bln (exp. 5bln) Current FY Rev. 91-92bln (exp. 88.82bln), adj. EPS 35-36 (prev. view 35.5-36.5, exp. 33.93)
ORIGINAL · NewsquawkEli Lilly and Company (LLY) Q3 2026 (USD): adj. EPS 7.48 (exp. 5.68), Revenue 24.4bln (exp. 22.58bln); Mounjaro 10.7bln (exp. 9.95bln), Zepbound 5.3bln (exp. 5bln) Current FY Rev. 91-92bln (exp. 88.82bln), adj. EPS 35-36 (prev. view 35.5-36.5, exp. 33.93)
StockNow breaking-news AI analysis
The breaking-news item reports Q3 results above expectations and current full-year revenue guidance above expectations, while adjusted EPS guidance is below the previous view.
Related stocks
1 stocksWhat do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.
